MIT researchers have secured up to $38 million from ARPA‑H for a four‑year project named PYTHIA, aiming to create a wearable patch that continuously monitors biomarkers of heart failure and sepsis. The patch is powered by the patient’s body heat and samples interstitial fluid beneath the skin, where disease‑related molecules exist at very low concentrations. A chemical reaction binds the biomarkers to specific reagents, and advanced microelectronics measure the resulting signal with clinical‑grade sensitivity. Because the device records data continuously, on‑chip AI models translate raw measurements into actionable information for clinicians, effectively providing a blood‑test‑like readout every 15 minutes. The effort is led by Professor Ahmad Bahai (EECS) and involves faculty from EECS, Chemistry, Chemical Engineering, as well as clinical and industry partners. The roadmap includes chip development, pre‑clinical and clinical trials, and eventual commercial scale‑up. PYTHIA grew out of MIT’s Health Sciences and Semiconductors (HS+S) program, building on prior continuous glucose‑monitor work to deliver personalized, real‑time health interventions. Review: By integrating microelectronics, biosensing chemistry, and AI, the project could dramatically improve early diagnosis and treatment monitoring, advancing wearable medical technology toward real clinical use.